Compare Biogen Inc (BIIB) vs Carnival Corp (CCL) Price & Performance

Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.

Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.

Carnival Corporation (CCL) trades at $27.77, showing minimal daily movement with a 0.07% gain. The stock demonstrates strong fundamental recovery with revenue growing from $12.2B in 2022 to $26.6B in 2025, while net income turned positive at $2.76B. Technical indicators show bearish momentum despite neutral oscillators, with key support at $27 and resistance at $28. Recent corporate developments include new voyage bookings through 2029 and continued dividend payments of $0.15 per share.

CCL presents a compelling recovery story with improving profitability and debt reduction, though near-term technical weakness and fuel cost risks persist. Analyst consensus remains bullish with a $35.18 price target representing 27% upside potential. The stock offers exposure to the rebounding cruise industry but faces sensitivity to economic conditions and operational execution challenges.